ClinicalTrials.gg
RecruitingNCT07700667Updated Oct 20, 2026

SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma

A Phase 2 interventional study of SKB500 and Tislelizumab in Esophageal Squamous Cell Carcinoma, sponsored by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.. Recruiting at 24 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (part of Sichuan Kelun Pharmaceutical Co.,Ltd.) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.
Updated Oct 20, 2026Eligibility revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 401 studies in Esophageal Squamous Cell Carcinoma with a site in China — 174 open to participants now, 213 under way, 32 of them phase 3. Esophageal Squamous Cell Carcinoma · China.

Planned enrollment
113th of 351
120 · median 70
Started
2026
with 47 others
Phase 2
212 of 401
96 open now
Primary completion
2028-12
later than 186 of 212 live
Registered
381st of 401
by date

Among the 401 studies in Esophageal Squamous Cell Carcinoma with a site in China, this one is the 113th largest by planned enrollment of the 351 interventional ones that give a count, is one of 48 that started in 2026, is one of 212 in phase 2, reaches primary completion later than 186 of the 212 other live ones, and was the 381st registered.

Esophageal Squamous Cell Carcinoma

678 studies on the registry are indexed under Esophageal Squamous Cell Carcinoma; 267 are open to participants now.

Browse Esophageal Squamous Cell Carcinoma studies →

Open to participants now

174 of the 401 studies in Esophageal Squamous Cell Carcinoma with a site in China are open now. Recruiting first, the newest first:

168 more — sign in →

All 174 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 180 Esophageal Squamous Cell Carcinoma studies recruiting now, 83 (46%) set no upper age limit and 76 (42%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 401 studies in Esophageal Squamous Cell Carcinoma with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety, tolerability and preliminary antitumor activity of SKB500 combinations in patients with Esophageal Squamous Cell Carcinoma. The study is divided into two parts: the safety run-in phase and the cohort expansion phase.

Read the detailed description

This is a Phase II, multicenter, open-label study to evaluate the safety, tolerability and preliminary antitumor activity of SKB500 combinations in patients with Esophageal Squamous Cell Carcinoma. The study is divided into two parts: the safety run-in phase and the cohort expansion phase.

03

Conditions studied

  • Esophageal Squamous Cell Carcinoma
04

Who can participate

The criteria were revised on the registry on Oct 20, 2026. See what changed

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 years and ≤75 years
  2. or cytologically confirmed unresectable locally advanced, recurrent or esophageal squamous cell carcinoma (ESCC), who are ineligible for curative-intent therapies:

    • Safety run-in phase (Cohort 1, 2 and 3): received no more than 1 for locally advanced or metastatic ESCC.
    • Safety run-in phase (Cohort 4) and cohort expansion phase: no prior systemic therapy for locally advanced or metastatic ESCC.
  3. Participants are required to provide tumor tissue samples for biomarker analysis.
  4. Has at least one according to (RECIST) Version 1.1.
  5. (ECOG) performance status of 0 or 1.
  6. ≥ 12 weeks.

Exclusion criteria

Exclusion Criteria:

  1. Histology or cytology confirms the presence of concurrent adenocarcinoma components.
  2. , brainstem, spinal, spinal cord compression, or active .
  3. Risk of esophagotracheal/esophagopleural fistula, or symptomatic invasion/compression of vital organs/major blood vessels.
  4. Active disease requiring systemic therapy within past 2 years.
  5. Weight loss ≥10% within 4 weeks prior to the first dose, or Nutritional Risk Index (NRI) \< 83.5.
  6. Severe infection within 4 weeks or active infection requiring systemic treatment within 2 weeks pre-dose.
  7. Uncontrolled comorbidities (e.g., decompensated liver cirrhosis, nephrotic syndrome, uncontrolled metabolic disorders, Grade ≥2 peripheral neuropathy).
  8. Cardiovascular/cerebrovascular events within 6 months pre-dose (e.g., Myocardial Infarction, unstable angina, acute/persistent ischemia, Grade 3/4 Heart Failure, symptomatic/uncontrolled arrhythmia, Cerebrovascular Accident, ).
  9. Uncontrolled hypertension, diabetes, or recurrent pleural/pericardial/abdominal effusion requiring drainage.
  10. History of interstitial lung disease (ILD) or noninfectious pneumonitis that require treatment, or currently has ILD/noninfectious pneumonitis.
  11. Unresolved to grade ≤ 1 of prior anti-cancer treatment toxicities criteria per v6.0.
  12. Previously received B7-H3-targeted agents, including antibody, antibody-drug conjugate (ADC), and other agents.
  13. Previously received any agent containing a topoisomerase I inhibitor (including chemotherapy and antibody-drug conjugate(ADC)).
  14. Pregnant or lactating women.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Cohort 1. SKB500+Tislelizumab

    Participants will receive Tislelizumab followed by SKB500

    Drug: SKB500 · Drug: Tislelizumab

  • Experimental
    Cohort 2. SKB500+Tislelizumab+5-FU

    Participants will receive Tislelizumab followed by SKB500, 5-FU

    Drug: SKB500 · Drug: Tislelizumab · Drug: 5 - FU

  • Experimental
    Cohort 3. SKB500+Tislelizumab+ Cisplatin

    Participants will receive Tislelizumab followed by SKB500, Cisplatin

    Drug: SKB500 · Drug: Tislelizumab · Drug: Cisplatin

  • Experimental
    Cohort 4. SKB500+Tislelizumab+ Cisplatin+5-FU

    Participants will receive Tislelizumab followed by SKB500, Cisplatin, 5-FU

    Drug: SKB500 · Drug: Tislelizumab · Drug: Cisplatin · Drug: 5 - FU

Interventions

  • DrugSKB500

    SKB500 will be administered as an intravenous infusion(IV), every 3 weeks on Day 1 of each 21-day cycle.

  • Tislelizumab will be administered as an intravenous infusion(IV) every 3 weeks on Day 1 of each 21-day cycle .

  • Cisplatin will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle.

  • Drug5 - FU

    5-FU will be administered as an intravenous infusion(IV) every 3 weeks on Day 1-5 of each 21-day cycle.

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR)

    Objective Response Rate (ORR) is the percentage of participants who achieved a best overall response of Complete Response (CR) or Partial Response (PR), assessed by investigator based on RECIST version 1.1.

    Time frame: up to 24 months

  2. Incidence and severity of adverse events (AEs) and serious adverse event(SAEs)

    Incidence and severity of adverse events (AEs) and serious adverse event(SAEs) graded by Common Terminology Criteria for Adverse Events (CTCAE) v6.0, as well as clinically significant abnormal laboratory findings.

    Time frame: up to 24 months

Secondary outcomes

  1. Progression-free survival (PFS)

    Progression-free survival (PFS) was defined as the time from baseline to the earliest date of the first objective documentation of progressive disease (PD) or death due to any cause.

    Time frame: up to 24 months

  2. Duration of response (DOR)

    Duration of Response (DOR) was defined as the time from the date of the first documentation of objective response (complete response\[CR\] or partial response \[PR\]) to the date of the first objective documentation of progressive disease (PD) or death due to any cause. DOR was measured for responding participants (PR or CR) only.

    Time frame: up to 24 months

  3. Disease control rate (DCR)

    Disease control rate (DCR) was defined as the sum of complete response (CR) rate, partial response (PR) rate, and stable disease (SD) rate.

    Time frame: up to 24 months

  4. Overall Survival (OS)

    The time from first dose to death from any cause.

    Time frame: up to 24 months

  5. Pharmacokinetic Parameter Maximum Plasma Concentration (Cmax) of SKB500-ADC, SKB500-TAB and free payload

    Cycle 1, 2, 4, 6, 8: pre-dose, post-dose; 12,16, every 8 cycles starting from Cycle 16 Day 1: pre-dose(each cycle is 21 days).

    Time frame: up to 24 months

  6. Pharmacokinetic Parameter Minimum Plasma Concentration (Cmin) of SKB500-ADC, SKB500-TAB and free payload

    Cycle 1, 2, 4, 6, 8: pre-dose, post-dose; 12,16, every 8 cycles starting from Cycle 16 Day 1: pre-dose(each cycle is 21 days) .

    Time frame: up to 24 months

  7. Anti-drug Antibodies (ADA) for SKB500

    Cycle 1, 2, 4, 8, every subsequent 8 cycles starting from Cycle 8 Day 1 : pre-dose (each cycle is 21 days).

    Time frame: up to 24 months

Other outcomes

  1. Biomarkers

    Correlation between the expression level of PD-L1, B7-H3, SLFN11 in tumor tissues and the efficacy.

    Time frame: Baseline, tumor tissue samples should be provided for PD-L1, B7-H3, SLFN11 testing

07

Study locations

24 of 24 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Dec 2028, 28 months after the start.

Of 173 phase 2 interventional studies under Esophageal Squamous Cell Carcinoma, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 52. This study's planned 28 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 8, 2026
First posted
Jul 14, 2026
StartActual
Aug 13, 2026
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2029
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
1 inclusion criterion edited; 2 exclusion criteria edited
What changed in the criteria
Inclusion criteria
  • EditedSafety run-in phase (Cohort 4), randomized enrollment phase and cohort expansion phase: no prior systemic therapy for locally advanced or metastatic ESCC.
Exclusion criteria
  • EditedPreviously received B7-H3-targeted agents, including antibody, antibodydrugantibody-drug conjugate (ADC), and other agents.
  • ChangedBefore Previously received treatment with an ADC that consists of a topoisomerase l inhibitor.Now Previously received any agent containing a topoisomerase I inhibitor (including chemotherapy and antibody-drug conjugate(ADC)).
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Eligibility 1 inclusion criterion edited; 2 exclusion criteria edited
    What changed in the criteria
    Inclusion criteria
    • EditedSafety run-in phase (Cohort 4), randomized enrollment phase and cohort expansion phase: no prior systemic therapy for locally advanced or metastatic ESCC.
    Exclusion criteria
    • EditedPreviously received B7-H3-targeted agents, including antibody, antibodydrugantibody-drug conjugate (ADC), and other agents.
    • ChangedBefore Previously received treatment with an ADC that consists of a topoisomerase l inhibitor.Now Previously received any agent containing a topoisomerase I inhibitor (including chemotherapy and antibody-drug conjugate(ADC)).
    + 1 other change: description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07700667
Responsible party
Sponsor
First posted
Jul 14, 2026
Start date
Aug 13, 2026
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Oct 20, 2026

Study contacts

Qing Yan
Contact
qingyan@kelun.com
028-67255480

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SKB500

Start the discussion